Diabetics receiving protamine-containing insulin formulations are known to develop an allergy to protamine [24] due to the production of IgE antibodies [25], and are 40 to 50-fold more likely to develop acute adverse events when administered the peptide for heparin reversal [26,27]. The gene discussed is INS; the disease is Allergy.